Biobot Analytics Inc.

Biobot Analytics Inc., a self-certified small disadvantaged business based in Cambridge, Massachusetts, provides wastewater-based epidemiology and laboratory testing services to federal health and drug-control agencies as a prime contractor (77% of recent awards), with capabilities spanning pathogen detection, illicit drug surveillance, and real-time public health monitoring through wastewater analysis.

The vendor's customer concentration is heavily skewed to a single anchor customer. The Centers for Disease Control and Prevention accounts for $31.1 million of the $37.1 million combined potential value across all awards — driven by a $31 million firm fixed price definitive contract awarded in April 2022 under total small business set-aside for commercial wastewater surveillance testing in support of the National Wastewater Surveillance System, which ran through February 2023 with testing of SARS-CoV-2 samples from up to 500 facilities nationwide. The Office of the National Drug Control Policy (Executive Office of the President) represents the second-largest customer by dollars at $2.4 million, with a September 2026 purchase order for real-time drug consumption data through wastewater testing, performance based in Washington, DC and running through September 2029. The National Institute on Drug Abuse and the Defense Health Agency each hold two awards; the NIH award was a $800 thousand SBIR Program Phase III action for wastewater-based monitoring of illicit drugs (September 2023 through August 2024), and Defense Health Agency placed a $130 thousand purchase order for SARS-CoV-2 analytical services under total small business set-aside (March 2022). The Office of Administration within the Executive Office of the President holds a $616 thousand purchase order from September 2025 for real-time drug consumption data collection and dissemination through wastewater testing, completing September 2026.

Activity shows a modest trajectory. The vendor received three awards in 2022 (anchored by the $31 million CDC contract), one in 2023, two in 2024, one in 2025, and two in 2026, with the most recent award just two weeks prior. Combined dollars obligated across all awards ($50.8 million) exceed combined potential value ($37.1 million) by 37 percent, indicating the vendor has drawn down or realized substantially more than the ceiling valuations across its contract portfolio. The vendor operates as a subcontractor on federal grant awards — three sub-award relationships with the Massachusetts Department of Public Health and Maine Department of Health and Human Services spanning wastewater testing and SARS-CoV-2 surveillance activities, with dates in 2024 and 2026.

SCI data shows minimal service-contract invoicing: $800 thousand across a single FY2024 record attributable to 0.3 FTEs, with no recorded invoicing in FY2022, FY2023, or FY2025. The SCI dataset captures only federal service contracts above the $150,000 reporting threshold and excludes goods, products, micro-purchases, and classified work; most of Biobot's work (particularly the $31 million CDC contract and the purchase orders for laboratory testing and analysis) falls outside SCI scope as goods or testing services rather than reportable service contracts. On the single SCI-reportable prime contract, government-paid rates ran approximately $1,099 per hour. The vendor performs all labor in-house on prime contracts; across SCI-reportable prime contracts, the sub-hours share averages zero percent.

Biobot's NAICS footprint centers on Testing Laboratories and Services (9 awards) with performance measured under Reference Laboratory Testing PSC codes (6 awards). The vendor does not hold parent vehicles such as GWACs, BPAs, or agency-wide IDIQs; all awards are direct purchase orders or definitive contracts from customer agencies.

We offer wastewater epidemiology services that include the design of a sampling program, laboratory testing of wastewater for Covid19, opioids, and other public health targets, data analysis and visualization into PDF reports and software dashboards/APIs.